{"count": 1, "results": [{"_id": "31607677", "pmid": 31607677, "title": "Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.", "journal": "Lancet Gastroenterol Hepatol", "authors": ["Pose E", "Napoleone L", "Amin A", "Campion D", "Jimenez C", "Piano S", "Roux O", "Uschner FE", "de Wit K", "Zaccherini G", "Alessandria C", "Angeli P", "Bernardi M", "Beuers U", "Caraceni P", "Durand F", "Mookerjee RP", "Trebicka J", "Vargas V", "Andrade RJ", "Carol M", "Pich J", "Ferrero J", "Domenech G", "Llopis M", "Torres F", "Kamath PS", "Abraldes JG", "Solà E", "Ginès P"], "date": "2020-01-01T00:00:00Z", "doi": "10.1016/S2468-1253(19)30320-6", "meta_date_publication": "2020 Jan", "meta_volume": "5", "meta_issue": "1", "meta_pages": "31-41", "score": 50242.39, "text_hl": "We observed no significant differences in alkaline phosphatase between the the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 40 mg/day plus @CHEMICAL_Rifaximin @CHEMICAL_MESH:D000078262 @@@rifaximin@@@ or the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 20 mg/day plus @CHEMICAL_Rifaximin @CHEMICAL_MESH:D000078262 @@@rifaximin@@@ groups compared with placebo. ", "citations": {"NLM": "Pose E, Napoleone L, Amin A, Campion D, Jimenez C, Piano S, Roux O, Uschner FE, de Wit K, Zaccherini G, Alessandria C, Angeli P, Bernardi M, Beuers U, Caraceni P, Durand F, Mookerjee RP, Trebicka J, Vargas V, Andrade RJ, Carol M, Pich J, Ferrero J, Domenech G, Llopis M, Torres F, Kamath PS, Abraldes JG, Solà E, Ginès P. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):31-41. PMID: 31607677", "BibTeX": "@article{31607677, title={Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.}, author={Pose E and Napoleone L and Amin A and Campion D and Jimenez C and Piano S and Roux O and Uschner FE and de Wit K and Zaccherini G and Alessandria C and Angeli P and Bernardi M and Beuers U and Caraceni P and Durand F and Mookerjee RP and Trebicka J and Vargas V and Andrade RJ and Carol M and Pich J and Ferrero J and Domenech G and Llopis M and Torres F and Kamath PS and Abraldes JG and Solà E and Ginès P}, journal={Lancet Gastroenterol Hepatol}, volume={5}, number={1}, pages={31-41}}"}}]}